Addiction Treatment Services
Baltimore, Maryland, 21224, United States
NCT Number: NCT00787735
This research is being done to:
* identify any emotional, behavioral or other troubling psychological problems that some people have who are seeking and receiving treatment for heroin or other drug use problems, * learn if providing additional psychiatric treatment services in the ATS drug abuse treatment program is as beneficial for and acceptable to patients as referring them to the Bayview Community Psychiatry Program to get help for their emotional, behavioral and other psychological problems.
Looking for future studies?
Notify Me18 year–80 year
All sexes
Interventional
Not applicable
Baltimore, Maryland, 21224, United States
This study will rigorously and systematically evaluate an integrated service delivery approach using a design that reduces many of the methodological limitations in earlier work. Study participants will include opioid abusers with a current psychiatric disorder. All study participants will receive comprehensive drug abuse treatment that includes adequate daily doses of methadone. Study participants will be randomly assigned to either an onsite and fully Integrated Substance Abuse and Psychiatric Care condition (ISAP-Integrated) or an offsite and non-integrated Parallel Substance Abuse and Psychiatric Care condition (PSAP-Parallel). Patients assigned to the ISAP condition will receive all of their ambulatory psychiatric care in the ATS treatment program; those assigned to the PSAP condition will be referred for matched "doses" of psychiatric care to the Community Psychiatry Program, which is located on the same campus as the ATS program. All drug abuse treatment services will be provided in the ATS program. Patients will be evaluated for 12 months on a range of outcome measures, including psychiatric medication and therapy adherence, drug abuse treatment adherence, changes in psychiatric symptoms, including posttraumatic stress disorder (PTSD), drug use, exposure to traumatic events, psychosocial functioning, and retention in both psychiatric and drug abuse treatment.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Rates of attendance to call counseling session over specific time points
Time frame: within first 90 days of randomized care
Time frame: 90, 180, and up to 365 days
Includes attendance to all of the following sessions: psychiatrist, individual psychiatric counseling, and group psychiatric counseling.
Time frame: 90, 180, and up to 365 days
Time frame: 90, 180, and up to 365 days
Time frame: 90, 180, and up to 365 days
Measured monthly using the Symptom Checklist 90-Revised (SCL90)
Time frame: 90, 180, and up to 365 days
Urinalysis tests are collected weekly. Results include tests for opioids, cocaine, benzodiazepines, and cannabis.
Johns Hopkins University
Other
Services Research: Psychiatric Comorbidity in Drug Abuse
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03970655
Chronic Rhinosinusitis (Diagnosis), Disease
Gainesville, Florida, United States
View Trial DetailsNCT07731217
Asthma, Asthma (Diagnosis)
Istanbul, Turkey (Türkiye)
View Trial DetailsNCT02328963
Cytomegalovirus Infection, Cytomegalovirus Infections
Bordeaux, France
View Trial DetailsNCT05468619
DNA Virus Infections, Disease
Birmingham, Alabama, United States
View Trial Details